Actinium Pharmaceuticals Investors: How to Lead Securities Fraud Lawsuit

Actinium Pharmaceuticals Investors to Take Action in Class Action Lawsuit

Investors in Actinium Pharmaceuticals, Inc. (NYSE: ATNM) are being reminded by the Rosen Law Firm about the significant opportunities available in a securities fraud lawsuit. Those who purchased shares between October 31, 2022, and August 2, 2024, are particularly encouraged to review their legal rights.

Important Dates and Actions

The fund, which aims to recover losses incurred during this time frame, has set a deadline of May 26, 2025, for lead plaintiff motions. Anyone who bought Actinium securities during this class period may be eligible for compensation under a contingency fee arrangement, meaning no upfront costs for participants.

To take part in the class action lawsuit, potential claimants can visit this link or contact Phillip Kim, Esq. through a toll-free line at 866-767-3653. They can also reach out via email at pkim@rosenlegal.com. Currently, the lawsuit has been filed, and individuals interested in being a lead plaintiff must notify the court by the aforementioned date. The lead plaintiff acts as a representative for the group in directing the litigation.

Why Choose Rosen Law Firm?

It's crucial for investors to choose counsel that has a successful history in handling similar cases. Some firms that send out notices may not have the same depth of experience or resources. The Rosen Law Firm stands out, focusing specifically on shareholder derivative litigation and securities class actions. They have a proven track record, highlighted by their historical achievements including securing a record class-action settlement against a Chinese company.

In the years prior, Rosen Law Firm has been ranked consistently at the top for their class action settlements, even achieving over $438 million in recoveries for clients in just one year. Their founding partner was recognized as a significant contributor within the plaintiffs' bar industry, cementing their reputation as a trusted legal partner for investors.

Case Details and Allegations

The allegations within the current lawsuit claim that during the specified class period, Actinium Pharmaceuticals made false statements and failed to disclose critical information concerning its operations and drug approval processes. Specific points of contention include:
1. Actinium's preliminary data concerning the Sierra Trial was unlikely to meet the FDA's stringent guidelines for approval of their Iomab-B Biologics License Application (BLA).
2. Additional analyses provided to the FDA attempting to counteract the unfavorable data from the Sierra Trial were likely insufficient to meet regulatory standards.
3. Due to these unmet conditions, the FDA might reject the review or approval of the BLA submitted by Actinium.
4. This series of misleading statements led investors to have an inflated view of Actinium’s business operations and future prospects.

As these details about the company came to light, investors experienced significant financial losses.

How to Participate

For those who want to join the action against Actinium Pharmaceuticals, options remain open. Potential participants can complete forms available online to express their interest in pursuing claims. Keep in mind that until a class is certified, individuals must either retain their counsel or can choose to remain uninvolved, though winning any recovery will not require serving as a lead plaintiff.

To stay updated, interested parties can follow the Rosen Law Firm on various social media platforms, including LinkedIn, Twitter, and Facebook. This maintains transparency and provides investors with the latest information regarding the proceedings.

Conclusion

Investors in Actinium Pharmaceuticals, who are facing the repercussions of potentially misleading information from the company, now have a pathway toward seeking restitution through legal means. The upcoming deadlines and selected legal representation can significantly influence the outcome. It's essential to stay informed and act swiftly to ensure the best chance for a favorable resolution.